Floatz logo

AK 127

Advanced or Metastatic Solid Tumours

Akesobio Australia Pty Ltdmonoclonal_antibodyEarly Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced or Metastatic Solid Tumours cohort.

Asset / SponsorPhaseRating
Apto-253
Aptose Biosciences Inc.
Phase 1CC
xy0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 1CC

Same molecule, other indications

AK 127 is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →